PRME Prime Medicine, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1894562 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY55.3%
TTM net income YoY-2.7%
TTM EPS YoY18.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-4,498.1%
Net margin-4,342.4%
FCF margin-3,607.4%
EBITDA margin-4,340.0%
Returns
ROE-146.8%
ROA-62.8%
ROIC (approx.)-2,278.6%
Asset turnover0.01x
Leverage & solvency
Liabilities / assets64.7%
Debt / equity0.00x
Current ratio4.84x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.81x
Accruals ratio-12.1%
Payout ratio—
Capex / revenue97.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $4.63M | $2.98M | $0 | $0 | $0 |
| R&D expense | $160.64M | $155.29M | $147.91M | $86.72M | $70.55M |
| SG&A expense | $52.35M | $50.16M | $43.39M | $29.82M | $13.92M |
| Operating income | -$208.35M | -$202.47M | -$204.79M | -$116.54M | -$84.47M |
| Income tax | $0 | $0 | -$279,000 | -$948,000 | -$486,000 |
| Net income | -$201.14M | -$195.88M | -$198.13M | -$121.82M | -$165.37M |
| EBITDA | -$201.03M | -$196.34M | -$200.14M | -$114.32M | -$83.91M |
| EPS (basic) | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 |
| EPS (diluted) | -1.35 | -1.65 | -2.18 | -4.19 | -14.19 |
| Weighted avg. shares (diluted) | 148.76M | 118.60M | 90.97M | 33.89M | 12.97M |
| Balance sheet | |||||
| Cash & equivalents | $63.03M | $196.54M | $55.07M | $201.12M | $198.54M |
| Short-term investments | $114.65M | — | — | $98.47M | $68.24M |
| Current assets | $181.29M | $211.89M | $142.98M | $296.62M | $270.58M |
| PP&E, net | $20.57M | $24.40M | $22.66M | $19.01M | $4.93M |
| Total assets | $342.73M | $297.51M | $193.85M | $360.31M | $301.86M |
| Current liabilities | $37.45M | $37.96M | $56.42M | $26.71M | $57.98M |
| Total liabilities | $221.87M | $144.36M | $60.78M | $44.04M | $62.30M |
| Shareholders' equity | $120.87M | $153.15M | $133.07M | $316.27M | -$156.24M |
| Shares outstanding | 180.51M | 131.16M | 97.38M | 97.21M | 32.41M |
| Cash flow statement | |||||
| Operating cash flow | -$162.56M | -$122.86M | -$165.41M | -$131.83M | -$34.08M |
| Capital expenditure | $4.53M | $7.29M | $8.72M | $16.09M | $4.15M |
| Free cash flow | -$167.09M | -$130.16M | -$174.14M | -$147.92M | -$38.23M |
| Investing cash flow | -$108.76M | $68.46M | $18.71M | -$47.10M | -$73.63M |
| Financing cash flow | $151.51M | $195.88M | $655,000 | $181.49M | $269.28M |
| Depreciation & amortization | $7.32M | $6.13M | $4.65M | $2.22M | $568,000 |
| Stock-based compensation | $29.27M | $26.07M | $13.91M | $6.46M | $1.75M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.